Polyphor awarded grant from CARB-X of up to $5.6M to support development of novel antibiotic against multi-drug resistant Gram-negative pathogens
CARB-X to fund the preclinical development and Phase I clinical trial of a novel OMPTA candidate.
Polyphor today announced that it has been awarded a non-dilutive award from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) to support the development of a novel OMPTA (Outer Membrane Protein Targeting Antibiotics) candidate addressing the deadliest and most resistant Gram-negative bacterial pathogens, including those designated as a critical concern by the World Health Organization (WHO).
Full PR available here